ARRIVENT BIOPHARMA, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
ARRIVENT BIOPHARMA, INC. (AVBP) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2026-03-05
- ARRIVENT BIOPHARMA, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2025 was $0.00.
- ARRIVENT BIOPHARMA, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2024 was $0.00.
- ARRIVENT BIOPHARMA, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2023 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-05 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |